Tonix Pharmaceuticals Holding (TNXP) Non-Current Deffered Revenue (2010 - 2018)

Tonix Pharmaceuticals Holding has reported Non-Current Deffered Revenue for 9 years, with the latest figure at $12000.0 in Q4 2018.

• On a quarterly basis, Non-Current Deffered Revenue fell 62.5% year-over-year to $12000.0 in Q4 2018; TTM through Dec 2018 was $12000.0, a 62.5% decrease from a year earlier, with the FY2018 full-year figure at $12000.0, down 62.5% from the prior year.
• Non-Current Deffered Revenue was $12000.0 for Q4 2018 at Tonix Pharmaceuticals Holding, up from $1000.0 in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $112000.0 in Q4 2015, with the low at $1000.0 in Q2 2018.
• Average Non-Current Deffered Revenue over 5 years is $48785.7, with a median of $49000.0 recorded in 2014.
• The sharpest annual moves came in 2014 and 2015: Non-Current Deffered Revenue sank 65.56% in 2014, then surged 1016.67% in 2015.
• Over 5 years, Non-Current Deffered Revenue stood at $68000.0 in 2014, then jumped by 64.71% to $112000.0 in 2015, then plunged by 60.71% to $44000.0 in 2016, then dropped by 27.27% to $32000.0 in 2017, then slumped by 62.5% to $12000.0 in 2018.
• The last three Non-Current Deffered Revenue figures came in at $12000.0 (Q4 2018), $1000.0 (Q2 2018), and $32000.0 (Q4 2017), per Business Quant data.